Titlebook: New Approaches to Drug Discovery; Ulrich Nielsch,Ulrike Fuhrmann,Stefan Jaroch Book 2016 Springer International Publishing Switzerland 201

Synthesize

,New Compound Classes: Protein–Protein Interactions,physiology, targeted modulation of PPIs would tremendously extend the “druggable” genome. In fact, in every disease a wealth of potentially addressable PPIs can be found making pharmacological intervention based on PPI modulators in principle a generally applicable technology. An impressing number o

Urgency

滔滔不绝的人

多节

痛恨

Predictive In Vivo Models for Oncology,dels. The increasing knowledge about the heterogeneity of cancer requested a substantial restructuring of the test systems for the different stages of development. To be able to cope with the complexity of the disease, larger panels of patient-derived tumor models have to be implemented and extensiv

光滑

集聚成团

Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug operties of lead compounds with the ultimate goal to attain a clinical candidate which achieves a concentration–time profile in the body that is adequate for the desired efficacy and safety profile. A thorough characterisation of the lead compounds aiming at the identification of the inherent PK lia

FUME

Nonclinical Safety and Toxicology,ntended use in humans. Hazards related to a drug have to be identified and the potential risks at the intended exposure have to be evaluated in comparison to the potential benefit of the drug. Preclinical safety is thus an integral part of drug discovery and drug development. It still causes signifi

IRATE

Impact of Biomarkers on Personalized Medicine,endous impact on drug development. With the emergence of more sensitive and specific technologies that are now able to be run in clinical settings and the ability to accurately measure biomarkers, there is a need to understand how biomarkers are defined, how they are used in clinical trials, and mos

Definitive

Modeling and Simulation of In Vivo Drug Effects,d development, and PK/PD modeling is common practice in all pharmaceutical companies. A recent analysis (Morgan et al., Drug Discov Today 17(9–10):419–424, 2012) revealed however that insufficient certainty in the integrity of the causal chain of fundamental pharmacological steps from drug dosing th